Leonard J. Appleman

Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates

Toni K. Choueiri, Susanna Jacobus, Joaquim Bellmunt et al. · Journal of Clinical Oncology · 2014 · 280 citations · Full text

Medicine, Oncology, Pharmacology +15

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

Amita Patnaik, Leonard J. Appleman, Anthony W. Tolcher et al. · Annals of Oncology · 2016 · 236 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

CD28 Costimulation Mediates T Cell Expansion Via IL-2-Independent and IL-2-Dependent Regulation of Cell Cycle Progression

Leonard J. Appleman, Alla Berezovskaya, Isabelle Grass et al. · The Journal of Immunology · 2000 · 202 citations

Life Sciences, Cell Biology, Immunology +17

CD28 Costimulation Mediates Down-Regulation of p27<i>kip1</i> and Cell Cycle Progression by Activation of the PI3K/PKB Signaling Pathway in Primary Human T Cells

Leonard J. Appleman, André A. F. L. van Puijenbroek, Kirstin M. Shu et al. · The Journal of Immunology · 2002 · 199 citations · Full text

Life Sciences, Cell Biology, Immunology +17

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

Joseph P. Eder, Geoffrey I. Shapiro, Leonard J. Appleman et al. · Clinical Cancer Research · 2010 · 193 citations · Full text

Medicine, Oncology, Pharmacology +17